$TARA
Protara Therapeutics, Inc.

2015 Q3 Form 10-Q Financial Statement

#000117184315006275 Filed on November 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q4 2014 Q3
Revenue $2.948M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.000M $1.400M $1.040M
YoY Change 92.31% 81.82% 10.64%
% of Gross Profit
Research & Development $3.078M $1.870M $1.773M
YoY Change 73.6% 83.33% 82.78%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $5.082M $3.273M $2.814M
YoY Change 80.6% 82.85% 47.33%
Operating Profit -$5.082M $134.0K
YoY Change -3892.54%
Interest Expense $10.00K
YoY Change -101.45%
% of Operating Profit
Other Income/Expense, Net -$301.0K $10.50M -$5.315M
YoY Change -94.34% 13025.0% 26475.0%
Pretax Income -$5.380M $7.230M -$5.180M
YoY Change 3.86% -401.25% 146.67%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.383M $7.233M -$5.181M
YoY Change 3.9% -401.38% 146.71%
Net Earnings / Revenue -175.75%
Basic Earnings Per Share
Diluted Earnings Per Share -$13.12M $23.32M -$14.80M
COMMON SHARES
Basic Shares Outstanding 16.46M 11.44M 240.6K
Diluted Shares Outstanding 12.30M 240.6K

Balance Sheet

Concept 2015 Q3 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.50M $83.60M $21.70M
YoY Change 224.88% 1507.69%
Cash & Equivalents $35.98M $68.84M $3.239M
Short-Term Investments $34.60M $14.80M $18.50M
Other Short-Term Assets $800.0K $1.000M $200.0K
YoY Change 300.0% 400.0%
Inventory
Prepaid Expenses $829.0K $1.006M
Receivables
Other Receivables
Total Short-Term Assets $71.38M $84.60M $21.90M
YoY Change 225.92% 1496.25%
LONG-TERM ASSETS
Property, Plant & Equipment $221.0K $83.00K $100.0K
YoY Change 121.0% -17.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $686.0K $114.0K $2.200M
YoY Change -68.82% -62.0%
Total Long-Term Assets $907.0K $197.0K $2.300M
YoY Change -60.57% -50.75%
TOTAL ASSETS
Total Short-Term Assets $71.38M $84.60M $21.90M
Total Long-Term Assets $907.0K $197.0K $2.300M
Total Assets $72.28M $84.80M $24.20M
YoY Change 198.69% 1387.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $591.0K $917.0K $1.000M
YoY Change -40.9% 129.25%
Accrued Expenses $2.235M $1.421M $1.600M
YoY Change 39.69% 42.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.168M $2.338M $2.700M
YoY Change 17.33% -76.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $84.00K $11.90M
YoY Change -99.29%
Total Long-Term Liabilities $84.00K $0.00 $11.90M
YoY Change -99.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.168M $2.338M $2.700M
Total Long-Term Liabilities $84.00K $0.00 $11.90M
Total Liabilities $3.252M $2.338M $14.60M
YoY Change -77.73% -76.14%
SHAREHOLDERS EQUITY
Retained Earnings -$124.9M -$109.9M
YoY Change
Common Stock $16.00K $16.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $69.03M $82.46M $9.600M
YoY Change
Total Liabilities & Shareholders Equity $72.28M $84.80M $24.20M
YoY Change 198.69% 1387.68%

Cashflow Statement

Concept 2015 Q3 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$5.383M $7.233M -$5.181M
YoY Change 3.9% -401.38% 146.71%
Depreciation, Depletion And Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$3.910M -$2.050M -$3.710M
YoY Change 5.39% 17.14% 144.08%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K $0.00 -$10.00K
YoY Change 1200.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $23.19M $3.690M -$1.680M
YoY Change -1480.36% -259.74% -321.05%
Cash From Investing Activities $23.06M $3.680M -$1.680M
YoY Change -1472.62% -258.62% -321.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 63.97M -10.00K
YoY Change -500.0% -100.23%
NET CHANGE
Cash From Operating Activities -3.910M -2.050M -3.710M
Cash From Investing Activities 23.06M 3.680M -1.680M
Cash From Financing Activities 40.00K 63.97M -10.00K
Net Change In Cash 19.19M 65.60M -5.400M
YoY Change -455.37% -1711.79% -252.11%
FREE CASH FLOW
Cash From Operating Activities -$3.910M -$2.050M -$3.710M
Capital Expenditures -$130.0K $0.00 -$10.00K
Free Cash Flow -$3.780M -$2.050M -$3.700M
YoY Change 2.16% 17.82% 143.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
prto Accretion Of Redeemable Convertible Preferred Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue
prto Accretion Of Redeemable Convertible Preferred Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue
5686000
prto Change In Fair Value Of Investor Rights And Obligation
ChangeInFairValueOfInvestorRightsAndObligation
prto Change In Fair Value Of Investor Rights And Obligation
ChangeInFairValueOfInvestorRightsAndObligation
-5344000
prto Foreign Currency Remeasurement Gain Loss
ForeignCurrencyRemeasurementGainLoss
-29000
prto Foreign Currency Remeasurement Gain Loss
ForeignCurrencyRemeasurementGainLoss
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193919000
CY2002Q1 prto Royalty Payment Percentage Of Net Sales
RoyaltyPaymentPercentageOfNetSales
0.025
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
591000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
917000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-580000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-18000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2235000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1421000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
192324000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
611000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
185000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1494000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
234000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
742000
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1801000
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9375000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1801000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9375000
CY2015Q3 us-gaap Assets
Assets
72284000
CY2014Q4 us-gaap Assets
Assets
84798000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
71377000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
84601000
CY2015Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
70208000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83585000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
6510000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
6508000
CY2015Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
34565000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
14755000
CY2014 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
CY2014 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
-2000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2739254
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1947849
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35983000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68840000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2793000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3239000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-32857000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
446000
CY2015Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
70500000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16479508
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16448455
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16479508
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16448455
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
16000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5380000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5169000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15023000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10586000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-67.65
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-29000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-314000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-440000
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-14000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-426000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-314000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2004000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1041000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5882000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2697000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
115000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
214000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
488000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1275000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2948000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
81000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-857000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
13000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
181000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2234000
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
CY2015Q3 us-gaap Investment Income Net
InvestmentIncomeNet
34000
CY2014Q3 us-gaap Investment Income Net
InvestmentIncomeNet
10000
us-gaap Investment Income Net
InvestmentIncomeNet
111000
us-gaap Investment Income Net
InvestmentIncomeNet
13000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
139000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
139000
CY2015Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
14000
CY2014Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
38000
CY2015Q3 us-gaap Liabilities
Liabilities
3252000
CY2014Q4 us-gaap Liabilities
Liabilities
2338000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72284000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84798000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3168000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2338000
CY2015Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
426000
CY2015Q3 us-gaap Loans Pledged As Collateral
LoansPledgedAsCollateral
14000
CY2014Q4 us-gaap Loans Pledged As Collateral
LoansPledgedAsCollateral
39000
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">1.</div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Organization and Operations</div></div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0">Proteon Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease. The Company was formed in June 2001 and incorporated on March 24, 2006. During 2013, the Company formed a wholly-owned subsidiary, organized in the United Kingdom, Proteon Therapeutics Limited. As of September 30, 2015, there has been no activity in this subsidiary other than its formation. During 2014, the Company formed a wholly-owned Massachusetts Securities Corporation subsidiary as a holding company for its available-for-sale investments, Proteon Securities Corp. The Company completed its initial public offering of its common stock, $0.001 par value per share (&#x201c;Common Stock&#x201d;) on October 27, 2014 (the &#x201c;IPO&#x201d;). Since inception, the Company has been primarily involved in research and development activities.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0">The Company devotes substantially all of its efforts to product research and development, initial market development and raising capital. The Company has not generated any product revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, competition from other companies, the need for development of commercially viable products and the need to obtain adequate additional financing to fund the development of its product candidates. The Company is also subject to a number of risks similar to other companies in the biotechnology industry, including regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and dependence on key individuals.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0">As of September 30, 2015, the Company had cash, cash equivalents and available-for-sale investments of $70.5 million. The Company believes that its existing cash, cash equivalents and available-for-sale investments will be sufficient to fund operations and capital expenditures into the fourth quarter of 2017. The Company had an accumulated deficit of $124.9 million as of September 30, 2015.</div></div>
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
101000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
24548000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-20549000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16162000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12380000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7940000
us-gaap Net Income Loss
NetIncomeLoss
-15035000
us-gaap Net Income Loss
NetIncomeLoss
-10575000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-5383000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-5181000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5383000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7458000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15035000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16261000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
2006000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-301000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5315000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-352000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6268000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
5082000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
2814000
us-gaap Operating Expenses
OperatingExpenses
14683000
us-gaap Operating Expenses
OperatingExpenses
7255000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5082000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
134000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14683000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4307000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
462000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
42000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
84000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
168000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
168000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
686000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
114000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2015Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
342000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-335000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5325000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-463000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5424000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
452000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
66136000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
19697000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
171000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
829000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1006000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
25000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
43752000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
3580000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
49000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
221000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
83000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3078000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1773000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8801000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4558000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124909000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109874000
CY2015Q3 us-gaap Revenues
Revenues
CY2014Q3 us-gaap Revenues
Revenues
2948000
us-gaap Revenues
Revenues
us-gaap Revenues
Revenues
2948000
us-gaap Royalty Expense
RoyaltyExpense
0
CY2015Q3 us-gaap Security Deposit
SecurityDeposit
14000
us-gaap Share Based Compensation
ShareBasedCompensation
1494000
us-gaap Share Based Compensation
ShareBasedCompensation
234000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
775789
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
589924
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7709000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13061000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1235526
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1800262
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.19
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
12403000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1683543
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.91
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.68
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8310000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y73D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y36D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y146D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y109D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25188
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
69032000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
82460000
CY2015Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
CY2014Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-2277000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-5686000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.65pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include, but are not limited to, estimates related to convertible notes, stock-based compensation expense, clinical trial accruals and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.65pt">The Company historically utilized significant estimates and assumptions in determining the fair value of its Common Stock. The Company utilized various valuation methodologies in accordance with the framework of the 2004 and 2013 American Institute of Certified Public Accountants Technical Practice Aids, <div style="display: inline; font-style: italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</div>, to estimate the fair value of its Common Stock prior to its IPO. Each valuation methodology included estimates and assumptions that required the Company&#x2019;s judgment.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.65pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.65pt">These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of Preferred Stock, the superior rights and preferences of securities senior to the Company&#x2019;s Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of Common Stock at each valuation date and materially affected the financial statements.</div></div></div></div></div></div></div></div></div></div>
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16466945
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
240610
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16455257
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
240375

Files In Submission

Name View Source Status
0001171843-15-006275-index-headers.html Edgar Link pending
0001171843-15-006275-index.html Edgar Link pending
0001171843-15-006275.txt Edgar Link pending
0001171843-15-006275-xbrl.zip Edgar Link pending
exh_101.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gff10q_111115p.htm Edgar Link pending
prto-20150930.xml Edgar Link completed
prto-20150930.xsd Edgar Link pending
prto-20150930_cal.xml Edgar Link unprocessable
prto-20150930_def.xml Edgar Link unprocessable
prto-20150930_lab.xml Edgar Link unprocessable
prto-20150930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending